Good morning, welcome to the 2026 annual meeting of shareholders of Summit Therapeutics Inc. We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and we are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the company's investor relations website for updates. At this time, I would like to introduce Summit's Chairman and Co-Chief Executive Officer, Bob Duggan. Please go ahead.
Thank you very much. Good morning, ladies and gentlemen. It is my pleasure to welcome each of you to the 2026 annual shareholders meeting for Summit Therapeutics and to call this meeting to order. Attending this meeting virtually is Deepak Bhandarkar, representing Pricewaterhouse LLP, the independent registered public accounting firm for us for fiscal year 2026, subject to shareholder ratification at this meeting. From our management team today, we have Dr. Maky Zanganeh, our Co-Chief Executive Officer and President, a member of our Board of Directors. Manmeet Soni, our Chief Operating O fficer and Chief Financial Officer, and a member of our Board of Directors. Dave Gancarz, our Chief Business and Strategy Officer. We also have Adam Finerman, a member of our external counsel team from BakerHostetler. Dave Gancarz will act as secretary of the meeting and will advise us to certain procedural items.
Good morning. Today's presentation, as well as the rules of conduct, are available in the meeting materials section on the virtual meeting website. Also available are the 2026 proxy statement and the 2025 annual report on Form 10-K. Before we begin, I would like to remind everyone that except for statements of historical fact, some statements made by our management team and some responses to questions that we may make today may be considered forward-looking statements based on our current expectations. Summit cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Please refer to our SEC filings for information about these risks and uncertainties. Summit undertakes no obligation to update these forward-looking statements except as required by law. Our chairman will describe how we will conduct the meeting.
First, there are some statements that must be made regarding notice of the meeting, the presence of a quorum, and such. There are four matters to be voted on. After the report on the votes, we will answer questions. Please hold any questions you may have until such time. The secretary has available for inspection a list of the stockholders entitled to vote. Mr. Secretary, please advise us concerning the mailing of the proxy statement and please report as to a quorum.
Mr. Chairman, the notice of annual meeting, the notice regarding the internet availability of proxy materials, was mailed to all stockholders of record on or about April 17th, 2026. We have appointed Adam Finerman, an Attorney at our outside counsel, BakerHostetler, to be the Inspector of Election. If anyone is planning on voting in person at this meeting, please follow the instructions received regarding voting at the meeting. The Inspector of Election will report as to a quorum.
Thank you. Mr. Chairman, proxies have been received totaling the majority of the total votes entitled to be cast, constituting a quorum. This meeting is being held pursuant to the notice of annual meeting, which was mailed to all stockholders.
Thank you. I declare that this 2026 annual meeting of stockholders of Summit Therapeutics Inc is duly and legally convened. The voting on all matters will be by stockholders present and stockholders represented by proxy. The items of business to be voted on will be set forth in the proxy statement. The first item of business is the election of directors. The board's nominees for terms expiring in 2027 are Robert W. Duggan, Chairman, Dr. Maky Zanganeh, Manmeet Soni, Kenneth Clark, Lead Independent Director, Dr. Robert Booth and Dr. Alessandra Cesano, Dr. Michelle Xia and Dr. Mostafa Ronaghi, and Jeff Huber. The next item of business is a proposal to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026, as set forth in the proxy statement. The Board of Directors recommends a vote for this proposal.
The next item of business proposal is a non-binding advisory vote to approve the compensation of our named executive officers. The Board of Directors recommends a vote for this proposal. The final item of business is a proposal to approve an amendment to the Summit Therapeutics 2020 Stock Incentive Plan to increase the number of shares of the company's common stock issuable under the plan by eight million shares. The Board of Directors recommends a vote for this proposal. At this time, any stockholders of record who wish to vote at the meeting should complete their voting. If you have already completed a proxy, there's no need to complete a ballot in order to vote. The polls for each matter to be voted on at this meeting are hereby declared open.
If any stockholder who wishes to vote at the meeting has not submitted his or her votes and needs more time, please so indicate. All votes are now in. I declare the polls closed. The Inspector of Election has taken charge of the ballots cast and will tabulate the vote and submit a report in writing to the Secretary. I will now turn matters over to the Secretary to describe the preliminary report of the election results prepared by the Inspector of Election. Dave?
Mr. Chairman, the Inspector of Election has presented me with his preliminary report. It has been determined that each of the nine directors nominated by the board has been elected by a plurality of votes cast, and the ratification of PricewaterhouseCoopers LLP U.S. as the independent registered public accounting firm has been approved. Shareholders also approved the compensation of our named executive officers and the amendment to the 2020 Stock Incentive Plan. The final results will be available next week on the company's website, www.smmttx.com, under the Investors tab, along with an archived recording of this meeting. We also intend to disclose the final results on Form 8-K within four business days of this meeting. Thank you.
Thank you very much. In accordance with the report of the Inspector, I hereby affirm that such report has been accepted and ask that the Secretary record in such the meetings of this meeting that he will prepare. The business of this meeting has now been completed, and I declare that the 2026 Annual Meeting of stockholders of Summit Therapeutics is now concluded. With our formal business completed, I hereby adjourn our 2026 Annual Meeting of stockholders. With that, I want to leave time for any questions from our shareholders. Now would be the time to bring those questions to the table if you have them.
At this time, there are no questions.
Okay. I want to thank very much all of you for attending our 2026 annual shareholders meeting. Have a wonderful rest of your day.
This concludes today's meeting. You may now disconnect.